| Autor: |
Jason S. Lewis, Michael J. Evans, Ian L. Fox, Jonathan D. Caen, Thomas R. Dilling, Megan M. Dacek, Kelly E. Henry |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.22476051.v1 |
| Popis: |
Supplementary Data file with additional experimental and figures. SUPPLEMENTAL FIGURE 1: Radiolabeling of [89Zr]Zr-transferrin as shown by instant thin layer chromatography. Radiochemical yield ranged from 60-70% and all radiochemical purity was >99%. SUPPLEMENTAL FIGURE 2: Protein analysis of drug treatment with BRD4 and ERK inhibitors in human PDAC cells via western blot. SUPPLEMENTAL FIGURE 3: Ex vivo immunohistochemistry of resected murine iKras*p53* tumors. SUPPLEMENTAL FIGURE 4: Dosing regimen for BRD4 and ERK inhibitors (indicated as "drug" in the scheme) over the course of 7 days, with a total of 12 doses, 12 hours apart. The timeline of [89Zr]Zr-transferrin radiotracer administration is indicated on day 5, with PET imaging and biodistribution on day 7, 48 h post-injection with the radiotracer. SUPPLEMENTAL FIGURE 5: Ex vivo immunohistochemistry of resected human PDAC tumors pre and post-treatment with JQ1. Differences in MYC and TfR protein expression can be observed in tumors that responded to JQ1 treatment with regards to [89Zr]Zr-transferrin uptake in vivo. SUPPLEMENTAL FIGURE 6: PET imaging of [89Zr]Zr-Transferrin uptake in vehicle vs. SCH772984-treated animals bearing BxPC-3 (KRAS-WT) xenografts. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
